Food and Drug Administration (United States)

Food and Drug Administration (United States)
United States Department of the Army · Public domain · source
Name	Food and Drug Administration
Formed	1906
Preceding1	United States Department of Agriculture Bureau of Chemistry
Headquarters	White Oak, Maryland
Employees	17,000 (approx.)
Budget	Discretionary budget authority (annual)
Parent agency	United States Department of Health and Human Services
Website	www.fda.gov

Food and Drug Administration (United States) The Food and Drug Administration is a federal regulatory agency responsible for protecting public health through regulation of Food safety, pharmaceutical drugs, medical devices, biologics, cosmetics, and tobacco products. It operates under the auspices of the United States Department of Health and Human Services and exercises statutory authority granted by landmark statutes such as the Federal Food, Drug, and Cosmetic Act and amendments including the Food and Drug Administration Modernization Act of 1997 and the Food and Drug Administration Safety and Innovation Act. The agency's actions intersect with many institutions and events including the United States Congress, the White House, and public health crises such as the 2009 swine flu pandemic and the COVID-19 pandemic.

History

The agency traces its origins to the United States Department of Agriculture's Bureau of Chemistry and legislative responses to public scandals like the publication of The Jungle and the passage of the Pure Food and Drug Act of 1906. The evolution of authority accelerated with the Federal Food, Drug, and Cosmetic Act of 1938 following incidents such as the Elixir sulfanilamide disaster, and was later shaped by events like the thalidomide tragedy which prompted modern drug regulation and the passage of the Kefauver Harris Amendment to strengthen drug efficacy requirements. Subsequent milestones include the creation of the Center for Drug Evaluation and Research, responses to the HIV/AIDS epidemic that influenced accelerated approval pathways, and structural shifts following the Food and Drug Administration Safety and Innovation Act and the agency's relocation to the White Oak Federal Research Center.

Organization and Leadership

The agency is organized into product- and function-based centers such as the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health, and the Center for Food Safety and Applied Nutrition. Leadership includes the Commissioner of Food and Drugs, appointed by the President of the United States with confirmation by the United States Senate, supported by deputy commissioners and chief counsel positions. The FDA collaborates with agencies like the Centers for Disease Control and Prevention, the National Institutes of Health, and international regulators such as the European Medicines Agency and World Health Organization during global health events and regulatory harmonization efforts.

Regulatory Authority and Responsibilities

Statutory authority derives from the Federal Food, Drug, and Cosmetic Act and related statutes including the Biologics Control Act, the Public Health Service Act, and the Tobacco Control Act. The FDA sets standards for safety, efficacy, and quality for products including prescription drugs, over-the-counter medications, vaccines, biologic therapies, medical devices, and food additives. It issues regulations, guidance documents, and product labeling requirements, and maintains systems such as the Adverse Event Reporting System to monitor post-market safety. The agency's jurisdiction overlaps with entities like the United States Department of Agriculture for meats and Environmental Protection Agency for pesticides, requiring interagency coordination exemplified in memoranda of understanding and joint responses to incidents.

Approval and Review Processes

Drug and biologic approvals are managed primarily through the New Drug Application and Biologics License Application pathways, with clinical trial oversight via Investigational New Drug applications and institutional review board interactions rooted in regulations influenced by the Nuremberg Code and the Declaration of Helsinki. The FDA employs expedited programs such as fast track designation, breakthrough therapy designation, priority review, and accelerated approval to address serious conditions, and utilizes advisory committees composed of external experts and stakeholders. Medical device clearance and approval involve processes like 510(k) submissions and premarket approval; foods and cosmetics follow notification, registration, and standard-setting pathways.

Enforcement and Compliance

The agency enforces requirements through inspectional authorities, warning letters, civil money penalties, product seizures, injunctions, and criminal referrals in coordination with the Department of Justice. Compliance activities include Good Manufacturing Practice inspections, recalls coordinated with firms and supply chain partners, and import refusals at ports of entry working with U.S. Customs and Border Protection. High-profile enforcement actions have involved pharmaceutical manufacturers, device makers, and retail chains, and have leveraged statutory tools under acts such as the Food Safety Modernization Act to enhance preventive controls and traceability.

Public Health Programs and Initiatives

The FDA administers initiatives targeting vaccine development, antimicrobial resistance, and pediatric therapeutics, and supports programs like the Orphan Drug Act incentives and the Pediatric Research Equity Act. During public health emergencies the agency issues Emergency Use Authorizations, coordinates with entities such as Operation Warp Speed and the Biomedical Advanced Research and Development Authority, and implements risk communication campaigns alongside partners including the Centers for Medicare & Medicaid Services and state health departments. The agency also engages in public-private partnerships, stakeholder guidance development, and global regulatory convergence efforts with agencies like Health Canada and the Pharmaceuticals and Medical Devices Agency (Japan).

Criticisms and Controversies

The FDA has faced criticism over issues including approval speed versus safety balance highlighted in debates after the Vioxx withdrawal, transparency of advisory committee processes, post-market surveillance limitations revealed during the opioid epidemic, and perceived regulatory capture concerns involving interactions with industry trade groups such as PhRMA. High-profile controversies include disputes over tobacco regulation implementation, the timing of emergency authorizations during the COVID-19 pandemic, and enforcement consistency in medical device clearance pathways. Calls for reform have led to congressional hearings, inspector general reviews, and legislative proposals addressing funding, user fee reliance from the Prescription Drug User Fee Act, and modernization of surveillance infrastructure.

Category:United States federal executive departments and agencies